At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 179 enrolled
Drug / intervention
IFX-1 +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Randomized, Double-blind, Placebo-controlled, Multicenter Phase II Study to Determine Efficacy and Safety of IFX-1 in Subjects With Moderate to Severe Hidradenitis Suppurativa
In Brief
A Phase 2 clinical trial evaluating IFX-1 and Placebo for Hidradenitis Suppurativa (HS). Completed, enrolled 179 participants across 41 sites in 9 countries.
Detailed Summary
The purpose of this study is to determine whether IFX-1 is safe and effective in the treatment of moderate to severe hidradenitis suppurativa.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsHidradenitis Suppurativa (HS)
CountriesBulgaria, Canada, Denmark, France, Germany, Greece, Netherlands, Poland, United States
CollaboratorsQuintiles, Inc.
Timeline
Phase 2CompletedFinished
201820192020202120222023202420252026
Enrollment StartFeb 2018
First PostedApr 2018
Primary CompletionMay 2019
Study CompletionJan 2020
TodayJul 2026
First PostedApr 4, 2018
Enrollment StartFeb 26, 2018
Primary CompletionMay 27, 2019
Study CompletionJan 27, 2020
TodayJul 2, 2026
Enrollment to primary: 1.3 yearsPosted 8.2 years ago
Interventions
IFX-1drug
Single IV infusions of IFX-1 diluted in sodium chloride.
Placebodrug
Placebo